公开(公告)号：US11939389B2

公开(公告)日：2024-03-26

申请号：US18170969

申请日：2023-02-17

Applicant: Novartis AG

Inventor： Aida Abujoub ,  John Blankenship ,  Dexiu Bu ,  Tony Fleming ,  Brian Holmberg ,  Connie Hong ,  Lu Huang ,  Chonghui Zhang

IPC: C07K16/28 ,  A61K35/17 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C12N5/0783 ,  A61K38/00

CPC classification number: C07K16/2878 ,  A61K35/17 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70578 ,  C12N5/0636 ,  A61K38/00 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33

Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

公开(公告)号：US20230183368A1

公开(公告)日：2023-06-15

申请号：US18170969

申请日：2023-02-17

Applicant: Novartis AG

Inventor： Aida Abujoub ,  John Blankenship ,  Dexiu Bu ,  Tony Fleming ,  Brian Holmberg ,  Connie Hong ,  Lu Huang ,  Chonghui Zhang

IPC: C07K16/28 ,  A61P35/00 ,  A61K35/17 ,  C07K14/725 ,  C07K14/705 ,  C12N5/0783

CPC classification number: C07K16/2878 ,  A61P35/00 ,  A61K35/17 ,  C07K14/7051 ,  C07K14/70578 ,  C12N5/0636 ,  A61K38/00

Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

公开(公告)号：US11608382B2

公开(公告)日：2023-03-21

申请号：US16439495

申请日：2019-06-12

Applicant: Novartis AG

Inventor： Aida Abujoub ,  John Blankenship ,  Dexiu Bu ,  Tony Fleming ,  Brian Holmberg ,  Connie Hong ,  Lu Huang ,  Chonghui Zhang

IPC: C07K16/28 ,  A61P35/00 ,  A61K35/17 ,  C07K14/725 ,  C07K14/705 ,  C12N5/0783 ,  A61K38/00

Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

公开(公告)号：US20220387486A1

公开(公告)日：2022-12-08

申请号：US17246351

申请日：2021-04-30

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Barbara Brannetti ,  Jennifer Brogdon ,  Boris Engels ,  Brian Walter Granda ,  Lu Huang ,  Ming Lei ,  Na Li ,  Jimin Zhang ,  Carla Patricia Pinto Guimaraes ,  Saar Gill ,  Marco Ruella ,  Regina M. Young

IPC: A61K35/17 ,  C07K16/28 ,  A61P35/00 ,  A61K38/17 ,  C12N15/85

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

公开(公告)号：US11149076B2

公开(公告)日：2021-10-19

申请号：US16256731

申请日：2019-01-24

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Hans Bitter ,  Jennifer Mary Bordeaux ,  Barbara Brannetti ,  Jennifer Brogdon ,  Naveen Kumar Dakappagari ,  Saar Gill ,  Steven Highfill ,  Lu Huang ,  Carl H. June ,  Ju Young Kim ,  Ming Lei ,  Na Li ,  Andreas Loew ,  Elena Orlando ,  Marco Ruella ,  Thai Tran ,  Jimin Zhang ,  Li Zhou

IPC: C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  A61K45/06 ,  A61K39/00 ,  A61K38/00

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.

公开(公告)号：US10525083B2

公开(公告)日：2020-01-07

申请号：US15727402

申请日：2017-10-06

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Barbara Brannetti ,  Jennifer Brogdon ,  Boris Engels ,  Brian Granda ,  Lu Huang ,  Ming Lei ,  Na Li ,  Jimin Zhang ,  Carla Guimaraes

IPC: A61K35/17 ,  A61P35/00 ,  A61K38/17 ,  C12N15/85 ,  C07K16/28 ,  A61K39/00

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

公开(公告)号：US12275795B2

公开(公告)日：2025-04-15

申请号：US17934064

申请日：2022-09-21

Applicant: NOVARTIS AG

Inventor： Aida Abujoub ,  John Blankenship ,  Tony Fleming ,  Brian Holmberg ,  Connie Hong ,  Lu Huang ,  Haihui Lu

IPC: C07K16/28 ,  A61K39/395 ,  A61K47/68 ,  A61P35/00 ,  C07K14/715 ,  C07K14/725 ,  C07K14/735 ,  C07K16/30 ,  C07K16/46 ,  C12N5/10 ,  C12N15/63 ,  A61K39/00

Abstract: The present disclosure provides BCMA binding molecules that specifically bind to human BCMA, conjugates comprising the BCMA binding molecules, and pharmaceutical compositions comprising the BCMA binding molecules and the conjugates. The disclosure further provides methods of using the BCMA binding molecules to treat cancers that express cell surface BCMA. The disclosure yet further provides recombinant host cells engineered to express the BCMA binding molecules and methods of producing the BCMA binding molecules by culturing the host cells under conditions in which the BCMA binding molecules are expressed.

公开(公告)号：USRE49847E1

公开(公告)日：2024-02-27

申请号：US17569389

申请日：2022-01-05

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Barbara Brannetti ,  Jennifer Brogdon ,  Boris Engels ,  Brian Granda ,  Lu Huang ,  Ming Lei ,  Na Li ,  Jimin Zhang ,  Carla Guimaraes ,  Saar Gill ,  Marco Ruella ,  Regina M. Young

IPC: A61K35/17 ,  A61K38/17 ,  C07K16/28 ,  C12N15/85 ,  A61P35/00 ,  A61K39/00

CPC classification number: A61K35/17 ,  A61K38/1774 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/2896 ,  C12N15/85 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/33

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

公开(公告)号：US11026976B2

公开(公告)日：2021-06-08

申请号：US16664223

申请日：2019-10-25

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Barbara Brannetti ,  Jennifer Brogdon ,  Boris Engels ,  Brian Walter Granda ,  Lu Huang ,  Ming Lei ,  Na Li ,  Jimin Zhang ,  Carla Guimaraes ,  Saar Gill ,  Marco Ruella ,  Regina M. Young

IPC: C07K16/28 ,  A61P35/00 ,  A61K38/17 ,  A61K39/00 ,  A61K35/17 ,  C12N15/85

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

公开(公告)号：US10253086B2

公开(公告)日：2019-04-09

申请号：US15094674

申请日：2016-04-08

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Hans Bitter ,  Jennifer Mary Bordeaux ,  Barbara Brannetti ,  Jennifer Brogdon ,  Naveen Kumar Dakappagari ,  Saar Gill ,  Steven Highfill ,  Lu Huang ,  Carl H. June ,  Ju Young Kim ,  Ming Lei ,  Na Li ,  Andreas Loew ,  Elena Orlando ,  Marco Ruella ,  Thai Tran ,  Jimin Zhang ,  Li Zhou

IPC: A61K38/00 ,  A61K39/00 ,  A61K45/06 ,  C07K16/28 ,  C07K14/705 ,  C07K14/725

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.